옵션 체인은 다양한 행사가격과 만기일에 대한 Quantum의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Quantum에 대한 시장 심리를 평가합니다..

Quantum (NASDAQ:QMCO) 주식, 옵션 체인

Quantum

Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data. The company provides solutions for the entire data lifecycle. The company specialize in solutions for video, images, audio, and other large files. The company's portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The company's Primary Storage Software and Systems include Myriad All-Flash Software-Defined Storage, StorNext Hybrid Flash/Disk File Storage Software, and Unified Surveillance Platform Software. Secondary Storage Software and Systems include ActiveScale Object Storage Software and DXi Backup Appliances. The firm derives the majority of its revenue from United States.

Equities

News

Markets

COST

DAVE

KULR

MSTR

NVDA

PLTR

QMCO

RCAT

SEZL

소형주는 2024년 주식시장에서 두드러진 성과를 보이며, 광범위한 시장 랠리 속에서 우량주를 크게 앞섰다. 무슨 일이 있었나: 올해 최고의 성과를 보인 종목들에서 소형주와 대형주 간의 차이는 특히 두드러졌다. 특히 소형주인 KULR 테크놀로지 그룹(NASDAQ:KULR)은 놀라운 2,494%의 수익률을 기록한 반면, 블루칩 주식인 엔비디아(NASDAQ:NVDA)는 여전히 인상적인 184% 상승률을 기록했다.

엔비디아는 2024년 블루칩의 스타였지만, 소형주에서 짜릿한 상승세를 기록한 선구자들

AMZN

TSLA

제롬 파월 연준 의장의 발언 이후 미국 주식 시장은 격동의 하루를 보냈다. 파월 의장이 향후 금리 인하에 대해 신중한 접근을 하겠다고 발표하면서 시장 변동성을 높였다. 마이크론 테크놀로지, 퀀텀 코퍼레이션, 메타, 아마존 및 테슬라

수요일 주목받은 주식: 마이크론 테크놀로지, 퀀텀 코퍼레이션, 메타, 아마존 및 테슬라

RGTI

리제티 컴퓨팅(NASDAQ:RGTI)의 주식이 금요일 52주 최고가를 경신하며 $4.39에 도달했다. 이는 지난 1년 동안 321.15%의 놀라운 상승률을 나타내며, 투자자들이 회사의 미래에 대해 긍정적인 신뢰를 가지고 있음을 시사한다.

리제티 컴퓨팅, 투자자 신뢰가 급증하여 52주 최고가 경신

Quantum Corp

General

ATEX

Anterix Launches Its AnterixAccelerator Initiative With Investment Of Up To $250M

Leveraging its differentiated commercial infrastructure, NeoGenomics expects to grow incremental topline revenue with contributions from the acquired business while operational consolidation efforts and synergies are expected to yield substantial annual cost reductions, which will be accretive to AEBITDA starting in 2026.

Health Care

NeoGenomics Acquired Pathline, Strengthening The Company's Commercial Presence In The Northeast U.S., Expanding Its Service Capabilities And Accelerating Growth In Molecular And Hematology-oncology Testing, Deal Terms Were Not Disclosed

Management

NOVA

Sunnova Appoints Paul Mathews As President And Chief Executive Officer

TECH

Bio-Techne Commences Shipping The Leo System, Powered By Simple Western Technology

TSEM

Tower Semiconductor, Innolight Expand Collaboration Utilizing Newest Silicon Photonics Platform, Now In Production And Ramping To High Volume

JP Morgan analyst Mark Murphy upgrades DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) from Underweight to Neutral and raises the price target from $70 to $75.

Upgrades

Price Target

Analyst Ratings

DOCU

JP Morgan Upgrades DocuSign to Neutral, Raises Price Target to $75

FCEL

Diversified Energy, FuelCell Energy And TESIAC To Form An Acquisition And Development Company Focus On Net-Zero Power From Natural Gas And Captured Coal Mine Methane

<ul>
<li>Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value &lt; 0.0001) assessed by automated office blood pressure at week 6.</li>
<li>Launch-HTN met a predefined endpoint with lorundrostat 50 mg dose achieving a 19.0 mmHg reduction in systolic blood pressure, and an 11.7 mmHg placebo-adjusted reduction (p-value &lt; 0.0001) assessed by automated office blood pressure at end of treatment, week 12.</li>
<li>Advance-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a highly statistically significant 7.9 mmHg placebo-adjusted reduction assessed by 24hr ABPM at end of treatment, week 12.</li>
<li>Lorundrostat demonstrated a favorable safety and tolerability profile in both pivotal trials</li>
</ul>

Biotech

MLYS

Mineralys Therapeutics Announced Topline Data From Its Pivotal Launch-HTN Phase 3 And Pivotal Advance-HTN Phase 2 Trials Of Lorundrostat For Uncontrolled Hypertension Or Resistant Hypertension, Both Trials Met Its Primary Endpoint

ALKT

Alkami Technology Intends To Offer $300M Of Convertible Senior Notes Due 2030 In Private Offering

HC Wainwright &amp; Co. analyst Ed Arce maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and raises the price target from $24 to $35.

CDTX

HC Wainwright & Co. Maintains Buy on Cidara Therapeutics, Raises Price Target to $35

SMTK

Smartkem Appoints Jonathan Watkins As COO

RDFN

Rocket Companies To Acquire Redfin In All-Stock Transaction Of $12.50/Share; Rocket Expects Combined Co. To Achieve Over $200M In Run-Rate Synergies Including $60M In Revenue Synergies

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ionis.com%2F&amp;esheet=54221346&amp;newsitemid=20250310238705&amp;lan=en-US&amp;anchor=Ionis+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=e0374aeb2777f987ad0557639a313466">Ionis Pharmaceuticals, Inc. </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) announced today that Ionis and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN. WAINZUA is the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector.
The approval by the European Commission (EC) follows the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.ionis.com%2Fnews-releases%2Fnews-release-details%2Fwainzua-eplontersen-recommended-approval-eu-chmp-treatment&amp;esheet=54221346&amp;newsitemid=20250310238705&amp;lan=en-US&amp;anchor=positive+opinion&amp;index=2&amp;md5=6dade3e35e1b46e15403a56558a1d0e4">positive opinion</a> of the Committee for Medicinal Products for Human Use (CHMP). The approval is based on the positive NEURO-TTRansform Phase 3 trial which showed that through 66 weeks, patients treated with WAINZUA demonstrated consistent and sustained benefit on the co-primary endpoints of serum transthyretin (TTR) concentration and neuropathy impairment measured by modified Neuropathy Impairment Score +7 (mNIS+7), and key secondary endpoint of quality of life (QoL) on the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) versus external placebo. WAINZUA continued to demonstrate a favorable safety and tolerability profile throughout the NEURO-TTRansform trial.
ATTRv-PN is a debilitating disease that leads to peripheral nerve damage with motor disability within five years of diagnosis and, without treatment, is generally fatal within a decade. WAINZUA is a once-monthly RNA-targeted medicine designed to reduce the production of TTR protein at its source.

Government

Regulations

IONS

Ionis and AstraZeneca Win EU Approval for WAINZUA, a Self-Injectable Treatment for Rare Nerve Disease

Needham analyst Mike Cikos reiterates Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Buy and maintains $28 price target.

Reiteration

CLBT

Needham Reiterates Buy on Cellebrite DI, Maintains $28 Price Target

JP Morgan analyst Brian Essex initiates coverage on SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Neutral rating and announces Price Target of $25.

Initiation

SAIL

JP Morgan Initiates Coverage On SailPoint with Neutral Rating, Announces Price Target of $25

Voyager Technologies (Voyager), a global leader in defense technology and space solutions, is expanding its partnership with Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) to develop AI-powered solutions for enhanced Space Domain Awareness, enabling the proactive mitigation of potential collisions and threats.

Voyager Teams Up With Palantir to Boost Space Safety Using AI-Powered Threat Detection

Cash and cash equivalents plus security investments of €17.4&nbsp;billion as of December 31, 2024

Earnings

Guidance

BNTX

BioNTech Expects 2025 Revenues Of €1.7B-€2.2B Versus Consensus Of €2.57B

The shares of Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) fell 6.1% during the pre-market trading session on Monday following a sharp decline in the price of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)
What Happened: Strategy Inc, a major Bitcoin holder witnessed a decline in its stock after the cryptocurrency&#8217;s price plummeted to $80,000 overnight, marking a 7% drop in the last 24 hours. This sharp fall is the most significant for the leading cryptocurrency since it fell below $80,000 ten days ago. 
This recent drop came in because President Donald Trump did not rule out a recession and stated that markets could go through a period of &#8216;transition&#8217;. 
Bitcoin&#8217;s decline impacted the broader market, causing other assets like Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) to slip into the red ahead of the new trading week. In the past 24 hours, the cryptocurrency market saw liquidations exceeding $615 million, with $540 million in bullish bets being wiped out.
Arthur Hayes, co-founder of BitMEX and Chief Investment Officer at Maelstrom Fund cautioned, &#8220;<a href="https://in.benzinga.com/trading-ideas/movers/25/03/44212362/bitcoin-ethereum-and-dogecoin-crash-as-trump-refuses-to-rule-out-recession-arthur-hayes-predicts-btc-to-retest-78000">Looks like BTC</a> will retest $78,000. If it fails, $75,000 is next in the crosshairs.&#8221;
SEE ALSO: <a href="https://www.benzinga.com/markets/equities/25/03/44214508/trumps-chaotic-policies-may-drive-investors-to-europe-says-analyst-quite-a-shift-in-the-world-order">Trump&#8217;s &#8216;Chaotic&#8217; Policies May Drive Investors To Europe, Says Analyst: &#8216;Quite A Shift In The World Order&#8217;</a>
Why It Matters: The recent downturn in the cryptocurrency market comes amid a broader discussion about the role of digital assets in the economy. 
Just two days before the plunge, the White House held its <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44187394/donald-trumps-crypto-summit-is-a-critical-moment-experts-say">first crypto summit</a>, which left some investors unhappy due to lack of clarity. This is likely because as per Trump&#8217;s executive order, the Strategic Bitcoin Reserve would consist solely of existing Bitcoin holdings that were previously confiscated by federal law enforcement agencies. The order did not provide a clear guarantee or timeline for the government to start making new cryptocurrency purchases directly.
The cryptocurrency industry is going through a major upheaval at the moment. The market&#8217;s reaction to Trump&#8217;s comments also highlights the influence of political and economic factors on cryptocurrency prices. Meanwhile, Strategy co-founder Michael Saylor proposed the U.S. government to acquire up to 25% of Bitcoin's total supply over the next decade, underscoring the growing importance of the cryptocurrency market.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/news/25/03/44211455/peter-lynchs-evergreen-market-advice-if-you-cant-find-growth-companies-in-innings-three-through-five-look-at-turnarounds">Peter Lynch&#8217;s Evergreen Market Advice: &#8216;If You Can&#8217;t Find Growth Companies In Innings Three Through Five, Look At Turnarounds&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

MSTR Stock Plunges Over 6% In Monday Pre-Market: What's Going On?

Jefferies analyst Laurence Alexander downgrades Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) from Buy to Hold and lowers the price target from $423 to $380.

Downgrades

Jefferies Downgrades Sherwin-Williams to Hold, Lowers Price Target to $380

Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) with a Buy and raises the price target from $8 to $25.

TRVI

Needham Maintains Buy on Trevi Therapeutics, Raises Price Target to $25

Press Releases

Quantum Scalar i7 RAPTOR Now Available

Quantum Computing Expected to be a Better Fit for Weather Forecasting as Latest Innovation is Changing the Industry

Quantum Announces Support for NVIDIA GPUDirect Storage with Myriad All-Flash File System

Quantum Computing Integrated with Artificial Intelligence Disrupting a Growing Number of Industries

Quantum Provides Clarification Regarding Recent Shareholder Transactions

Quantum Announces the Next Steps of its Debt Reduction Initiative

Quantum Announces Scalability Enhancements to its Myriad All-flash File System

Quantum to Release Fiscal Third Quarter 2025 Financial Results on Wednesday, February 12, 2025

Quantum Reports Fiscal Third Quarter 2025 Financial Results

Quantum Computing Solutions Big Influence on Commercial & Military Drone Applications Drastically Improving Operations

Comments

Quantum

Quantum (QMCO) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌